Company profile
CLIMB BIO, INC.
NASDAQ:CLYMBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BUDOPRUTUG | phase2 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07090655 | — | completed | 2025-08-11 | 2026-04-07 | Climb Bio, Inc. | A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers |
| NCT07248865 | phase1 | recruiting | 2025-12-02 | 2026-07-01 | Climb Bio, Inc. | A Phase 1 Study of CLYM116 in Normal Healthy Volunteers |
| NCT07011043 | phase1 | recruiting | 2025-07-10 | 2027-04-01 | Climb Bio, Inc. | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) |
| NCT07043946 | phase1_2 | recruiting | 2025-06-30 | 2027-08-01 | Climb Bio, Inc. | A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) |
| NCT07564596 | phase1_2 | recruiting | 2026-06-30 | 2027-09-01 | Climb Bio, Inc. | A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) |
FDA applications (0)
No records yet.